BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

The last days of 2012: Patent cases and empty seats

Oct. 22, 2012
By Mark McCarty
There are only 70 or so days left in 2012, but that doesn’t mean there isn’t a lot of critical activity still in play. Here are a couple of things to keep track of. November 6: Who will choose the new faces on the Supreme Court? Several members of the Supreme Court are approaching retirement, which makes the upcoming presidential election even more important. Justice Ruth Bader Ginsburg is 79 and nearly certain to vacate her seat before 2016. Justices Scalia and Kennedy are both 76, while Justice Breyer is 74. How many of these last three will hang it...
Read More

Washington roundup: Two cases tugging at patents as the Myriad appeal lingers

Oct. 22, 2012
By Mark McCarty

Washington roundup: Aetna unwilling to cover ankle replacement for failed prostheses

Oct. 19, 2012
By Mark McCarty

Washington roundup: FDA issues twin guidances for review times per MDUFA III

Oct. 18, 2012
By Mark McCarty

Washington roundup: FDA warning letter roundup lassoes device firms in China

Oct. 17, 2012
By Mark McCarty

Washington roundup: Anthem: MP-RAGE MRI a no-go for all indications

Oct. 16, 2012
By Mark McCarty

Washington roundup: CMS eyes PET coverage for detection of amyloid plaques

Oct. 15, 2012
By Mark McCarty

Washington roundup: JAMA article suggests public reporting shorts infarct patients

Oct. 12, 2012
By Mark McCarty

FDA and the compounding pharmacy story

Oct. 11, 2012
By Mark McCarty
Most of the entries here at the MDD Perspectives blog address med tech, but I’m going to go off topic and address the compounding pharmacy issue, because it is at risk of becoming an FDA issue. As we all know, the New England Compounding Pharmacy (NECP) is said to be the source of the tainted methylprednisolone injections that led to the multiple cases of meningitis, and now the predictable cry has gone out to have FDA regulate compounding pharmacies. The idea is understandable, but let’s find out what’s...
Read More

Washington roundup: Integrity agreement training mandates called burdensome

Oct. 11, 2012
By Mark McCarty
Previous 1 2 … 415 416 417 418 419 420 421 422 423 … 575 576 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing